Smoking Cessation

Abstract

Smoking cessation is a type of health behavior: the process of discontinuing tobacco use and sustaining abstinence against the pull of nicotine dependence. What makes it a model problem for psychology is that it is rarely a single decision and almost never a single attempt—it is a process that unfolds over stages, is defended by a pharmacological dependence and an automatized habit, and is lost and regained across repeated relapses before it holds. This article develops the construct across levels: how cessation is defined and classified, the stage and learning theories that describe how people change, the nicotine dependence and withdrawal that make quitting hard, the pharmacological and behavioral aids that raise success rates, and what current work says about electronic cigarettes and the cognitive mechanisms of relapse.

Keywords: smoking cessation, nicotine dependence, transtheoretical model, relapse prevention, nicotine replacement therapy

Most smokers who want to quit already know that smoking will harm them, have tried to stop before, and will try again—the typical successful quitter makes several attempts before one holds. Quitting is therefore not well described as a one-time choice between two options but as a process that is entered, abandoned, and re-entered, defended at every step by a dependence that is at once pharmacological and behavioral. Smoking cessation is the term the medical and psychological literature uses for this process, and its staged character, its vulnerability to relapse, and its responsiveness to treatment are the organizing problems of the field (Prochaska & DiClemente, 1983).

The stakes are large and the margins are treatable. Nicotine is among the most heavily reinforcing drugs of dependence, and the withdrawal that follows a quit attempt is a reliable, time-limited syndrome that drives many relapses in the first weeks (Benowitz, 2010; Hughes, 2007). Yet cessation is also one of the most studied behaviors in clinical psychology, with a well-mapped set of pharmacological and behavioral aids that measurably raise the odds of success. This article treats smoking cessation as a problem in the psychology of behavior change: how it is defined, how stage and learning theories describe it, why dependence and withdrawal resist it, and what the evidence says about helping it along.

What Smoking Cessation Is

Smoking cessation is the process of discontinuing the use of tobacco, together with the maintenance of abstinence over time. In the Medical Subject Headings vocabulary, Smoking Cessation is a descriptor filed at tree position F01.145.488.732, directly beneath health behavior, where it names the protective counterpart to the risk behavior of smoking itself: cessation is the action a person takes to remove an established hazard to health. The descriptor was introduced in 1992, reflecting the point at which stopping smoking had become a research object in its own right rather than merely the absence of a behavior.

The defining psychological fact about cessation is that it is a process, not an event. A person does not simply pass from smoker to non-smoker; they move through a sequence of motivational states, often over months or years, and the great majority relapse at least once before abstinence holds. This is why the field measures cessation not by a single quit date but by sustained abstinence at defined follow-up points—typically six or twelve months—and why the central explanatory problem is not why someone decides to quit but why the decision so often fails to stick (Prochaska et al., 1992). The behaviors that compose cessation—setting a quit date, managing withdrawal, avoiding or coping with cues, recovering from a lapse—are the targets that theory and treatment must address.

Models of Smoking Cessation

How does a person change an entrenched, pharmacologically defended behavior? The field answers at two levels—the motivational structure of the change process, and the learning and cognitive mechanisms that resist or enable it. No single theory owns the construct; each illuminates one facet, and Table 1 sets the major accounts side by side before the sections below take them in turn.

The most influential account of the change process is the transtheoretical model of James Prochaska and Carlo DiClemente, which grew directly out of the study of how smokers quit on their own (Prochaska & DiClemente, 1983). It holds that behavior change proceeds through an ordered series of stages: precontemplation (no intention to quit), contemplation (weighing it), preparation (intending to act soon), action (actively abstaining), and maintenance (sustaining abstinence). Crucially, the stages are not a one-way staircase; relapse returns a person to an earlier stage, and most cycle through the sequence several times, so the model is usually drawn as a spiral rather than a line. Its practical claim is that interventions should be matched to stage—consciousness-raising for a precontemplator, concrete action plans for someone preparing—because the same advice that helps a ready smoker is wasted on one who is not yet considering change (Prochaska et al., 1992).

The model is not without critics; a prominent critique argues that the stages are arbitrary divisions of a continuum and that stage-matched interventions have not reliably outperformed simpler approaches, so the framework may describe the phenomenology of quitting better than it guides treatment (West, 2005). Two further accounts address what sustains or breaks a quit attempt once made. Albert Bandura's self-efficacy theory holds that a person's confidence in their capacity to abstain—especially in tempting situations—predicts both whether they attempt to quit and whether they maintain abstinence, over and above their intention (Bandura, 1977). Icek Ajzen's theory of planned behavior locates the intention to quit upstream, as a product of attitudes toward quitting, perceived social norms, and perceived behavioral control (Ajzen, 1991). Relapse prevention, developed by Alan Marlatt and Judith Gordon, reframes maintenance itself as a set of coping skills: it identifies the high-risk situations—negative affect, social pressure, interpersonal conflict—in which lapses cluster and teaches smokers to anticipate and cope with them without smoking (Marlatt & Gordon, 1985).

A distinct cognitive account turns attention from the decision to the automaticity of the act itself. Stephen Tiffany's cognitive model of drug urges holds that smoking in a dependent person is largely governed by automatized action schemata that run off with little conscious control; craving becomes a conscious experience chiefly when those schemata are impeded—when a smoker cannot light up, or is actively resisting—and nonautomatic processes are recruited to manage the obstruction (Tiffany, 1990). The model reframes the urge not as the cause of smoking but as the subjective signature of a blocked routine, which is why cue-triggered relapse can occur with little deliberation and why craving spikes precisely under the effort to abstain (Figure 1).

Figure 1

Tiffany's Cognitive Model of Drug Urges

Nicotine Dependence and Withdrawal

Underneath the psychology of the decision sits a pharmacology that makes the decision hard to keep. Nicotine acts on nicotinic acetylcholine receptors to release dopamine in the brain's reward pathways, and repeated dosing produces the neuroadaptation, tolerance, and dependence characteristic of an addictive drug (Benowitz, 2010). The dependence is both physical and behavioral: a smoker titrates nicotine intake to maintain a preferred blood level, and the hundreds of daily hand-to-mouth repetitions bind the drug to a dense web of situational cues. The degree of physical dependence can be measured—the Fagerström Test for Nicotine Dependence quantifies it from a handful of items, chiefly how soon after waking a person smokes and how many cigarettes they consume—and the resulting score predicts how hard cessation will be and how much pharmacological help it will need (Heatherton et al., 1991).

When a dependent smoker stops, a reliable withdrawal syndrome follows: irritability, anxiety, difficulty concentrating, restlessness, increased appetite, and above all craving. The syndrome is time-limited—most symptoms rise within a day or two, peak in the first week, and largely resolve over two to four weeks, though craving can persist much longer—and its course is consistent enough to be treated as a validated clinical entity (Hughes, 2007). This temporal structure matters for cessation because it concentrates the risk of relapse in exactly the window when symptoms are worst, which is the rationale for front-loading pharmacological and behavioral support in the first weeks after a quit date.

Smoking is also, crucially, automatized. On Stephen Tiffany's cognitive model of drug urges, the behavior of a long-term smoker is controlled largely by fast, effortless automatic processes triggered by cues, and conscious urges arise mainly when those automatic action schemata are blocked—as they are during a quit attempt (Tiffany, 1990). The model reframes craving: it is not the cause of ordinary smoking, which runs off automatically, but the conscious signature of a thwarted routine, which is why a quitter can be ambushed by an urge in a smoking-associated situation without having formed any intention to smoke. Consistent with this, dependent smokers develop an attentional bias toward smoking cues—such cues automatically capture and hold attention—which helps explain how the environment reinstates craving and undermines maintenance (Field & Cox, 2008).

Pharmacotherapy and Behavioral Aids

The practical payoff of this understanding is a set of treatments that measurably raise quit rates. The best-established is nicotine replacement therapy (NRT)—patches, gum, lozenges, inhalers, and sprays that supply nicotine without tobacco smoke, blunting withdrawal while the behavioral habit is broken. A large body of randomized evidence, synthesized in a Cochrane review of well over a hundred trials, shows that all forms of NRT reliably increase the likelihood of long-term abstinence relative to placebo or no NRT, by roughly 50 to 60 percent in relative terms (Hartmann-Boyce et al., 2018). The effect is modest in absolute terms but consistent, and it is largest when NRT is combined with behavioral support that targets the cue-driven, skill-based side of maintenance that the drug alone does not touch.

Two non-nicotine medications complete the first-line pharmacological menu. Varenicline is a partial agonist at the nicotinic receptor, occupying it to blunt withdrawal while attenuating the reward from any cigarette that is smoked; bupropion is an antidepressant that also reduces craving and withdrawal through dopaminergic and noradrenergic action. A Cochrane overview and network meta-analysis that pools the full set of cessation-drug trials ranks varenicline the most effective single agent—more effective than either bupropion or a single form of NRT—with bupropion and NRT comparable to each other, which is why clinical guidelines present cessation pharmacotherapy as a graded menu rather than a single default (Cahill et al., 2013).

The most actively debated recent development is the electronic cigarette. A landmark randomized trial found that e-cigarettes were more effective than conventional NRT for cessation when both were accompanied by behavioral support (Hajek et al., 2019), and a Cochrane review that now pools many trials concludes with high certainty that nicotine-containing e-cigarettes increase quit rates compared with NRT and with behavioral support alone (Lindson et al., 2024). The finding is consequential but contested, because e-cigarettes are themselves nicotine-delivery devices with their own dependence potential and uncertain long-term effects, so their role as a cessation aid is weighed differently for an established adult smoker than for a population that includes never-smokers. The craving that treatment must ultimately manage remains the field's central mechanistic target, and current theoretical work continues to refine how craving should be conceptualized and measured (Sayette, 2016).

Worked Example

The effect of a cessation aid can be made quantitative, and translating a relative effect into an absolute one shows why a reliable treatment can still look unimpressive at the individual level. Suppose that, in a given population, the six-month abstinence rate for smokers quitting with brief advice but no medication is 10 percent. The Cochrane synthesis of nicotine replacement therapy estimates a relative risk of abstinence of about 1.55 for NRT versus control (Hartmann-Boyce et al., 2018). The expected abstinence rate with NRT is therefore the baseline multiplied by the relative risk:

0.10 × 1.55 = 0.155, or 15.5 percent.

The absolute benefit is the difference between the two rates:

0.155 − 0.10 = 0.055, or 5.5 percentage points.

The number needed to treat—how many smokers must use NRT for one additional person to be abstinent at six months who would not otherwise have been—is the reciprocal of that absolute difference:

NNT = 1 / 0.055 ≈ 18.

So about one in eighteen smokers treated gains a successful quit they would not have had unaided. Two lessons follow. First, a relative increase that sounds large (55 percent) corresponds to a single-digit gain in percentage points, because the baseline success rate is itself low—the arithmetic of relative versus absolute risk that governs all low-base-rate interventions. Second, because the absolute gain scales with the baseline, the same NRT applied in a setting with a higher unaided quit rate would avert more quits per hundred treated. At the population level, a 5.5-point gain applied to the millions who attempt to quit each year is a very large number of averted smoking careers, which is why a per-person effect this modest is still a public-health priority.

Discussion

The study of smoking cessation has moved from treating quitting as a test of willpower to understanding it as a staged, pharmacologically defended, and treatable process. Three findings carry most of the weight. The stage tradition established that readiness to change is not binary, so that effective help must meet smokers where they are rather than assuming everyone is prepared to act (Prochaska & DiClemente, 1983; Prochaska et al., 1992). The dependence research showed that abstinence provokes a reliable, time-limited withdrawal syndrome and that much of smoking is automatized rather than deliberate, which relocates the problem of relapse from weak resolve to cue-driven mechanism (Benowitz, 2010; Hughes, 2007; Tiffany, 1990). And the treatment research produced a graded menu of aids—NRT, behavioral support, and increasingly e-cigarettes—whose effects are modest per person but decisive at scale (Hartmann-Boyce et al., 2018; Lindson et al., 2024).

The convergence of these lines has reshaped how cessation is supported. If quitting is staged, defended by dependence, and lost to automatic cues, then the most effective interventions combine a pharmacological agent that blunts withdrawal with behavioral support that rebuilds the skills of maintenance and anticipates the high-risk situations in which lapses cluster (Marlatt & Gordon, 1985; Bandura, 1977). The transtheoretical model, once the field's organizing framework, is now held alongside pointed critiques of its stage construct, and the center of gravity has shifted toward treatments whose efficacy is measured in randomized trials rather than toward any single stage theory (West, 2005).

Current Directions

Contemporary work is concentrated on two fronts. The first is the role of electronic cigarettes, where the evidence has moved quickly: trials and the cumulative Cochrane synthesis now support nicotine-containing e-cigarettes as an effective cessation aid, even as questions about long-term safety and about use by non-smokers keep their place in tobacco policy unsettled (Hajek et al., 2019; Lindson et al., 2024). The second is the science of craving itself, where methodological and theoretical work continues to sharpen how urges should be defined, elicited, and measured—distinguishing tonic background craving from cue-provoked spikes and relating both to the automatic processes that drive relapse (Sayette, 2016; Field & Cox, 2008). The common thread is a move from global stage descriptions toward mechanistic, measurable targets—withdrawal, attentional capture, craving dynamics—that a treatment can be designed to hit.

Common Misconceptions

Quitting is a single decision that succeeds or fails by willpower.

Cessation is a process that most smokers cycle through several times before abstinence holds; relapse is a normal part of the sequence, not a sign of absent willpower, which is why stage-matched and relapse-prevention approaches treat it as expected (Prochaska et al., 1992; Marlatt & Gordon, 1985).

Craving is what makes smokers light up.

On Tiffany's model ordinary smoking runs off automatically, without conscious craving; urges become salient mainly when the automatic routine is blocked, as during a quit attempt. Craving is better understood as the signature of a thwarted habit than as the engine of everyday smoking (Tiffany, 1990).

Nicotine replacement just swaps one addiction for another.

NRT supplies nicotine without the combustion products that cause most smoking-related disease, at steadier, lower levels that blunt withdrawal while the behavioral habit is broken; randomized evidence shows it raises long-term abstinence over placebo (Hartmann-Boyce et al., 2018; Benowitz, 2010).

A modest per-person effect means a treatment is not worth using.

Because the unaided quit rate is low, a large relative benefit yields only a few percentage points per person—a number needed to treat of roughly eighteen for NRT—yet applied across the millions who try to quit each year that effect averts an enormous number of smoking careers (Hartmann-Boyce et al., 2018).

Glossary

Abstinence.

The state of refraining from tobacco use; in cessation research, usually measured as sustained non-smoking at a defined follow-up such as six or twelve months.

Attentional bias.

The tendency of smoking-related cues to automatically capture and hold a dependent smoker's attention, contributing to cue-driven craving and relapse.

Automatic processing.

In Tiffany's model, the fast, effortless, cue-triggered control of established smoking; conscious urges arise chiefly when this automatic routine is blocked.

Bupropion.

A non-nicotine antidepressant used as a first-line cessation medication, reducing craving and withdrawal through dopaminergic and noradrenergic action.

Craving.

A conscious, often cue-provoked urge to smoke; a core symptom of nicotine withdrawal and a central mechanistic target of cessation treatment.

Electronic cigarette.

A device that delivers nicotine as an inhaled aerosol without tobacco combustion; recent evidence supports nicotine-containing e-cigarettes as a cessation aid.

Fagerström Test for Nicotine Dependence.

A brief questionnaire measuring physical nicotine dependence, chiefly from time-to-first-cigarette and daily consumption; its score predicts cessation difficulty.

Health behavior.

The broader MeSH parent category of action affecting health, under which smoking cessation is classified as a protective subtype.

Lapse.

A single episode of smoking after a quit date; distinguished from relapse, the return to regular smoking, which a lapse may or may not precipitate.

Maintenance.

In the transtheoretical model, the stage of sustaining abstinence and guarding against relapse after the initial action of quitting.

Nicotine dependence.

The neuroadaptation, tolerance, and withdrawal produced by repeated nicotine exposure; the pharmacological core of the difficulty of quitting.

Nicotine replacement therapy.

Treatment supplying nicotine via patch, gum, lozenge, inhaler, or spray to blunt withdrawal during cessation; reliably raises long-term quit rates over placebo.

Number needed to treat.

The number of people who must receive a treatment for one additional favorable outcome; the reciprocal of the absolute risk difference between treatment and control.

Relapse prevention.

Marlatt and Gordon's approach treating maintenance as a set of coping skills for the high-risk situations in which lapses cluster.

Self-efficacy.

Bandura's construct of confidence in one's capacity to perform a behavior; in cessation, confidence in abstaining predicts quit attempts and their maintenance.

Stages of change.

The transtheoretical model's ordered sequence—precontemplation, contemplation, preparation, action, maintenance—through which behavior change is held to proceed.

Transtheoretical model.

Prochaska and DiClemente's stage model of intentional behavior change, developed from the study of how smokers quit, in which relapse returns a person to an earlier stage.

Varenicline.

A non-nicotine partial agonist at the nicotinic receptor used for cessation; it blunts withdrawal while attenuating the reward from a smoked cigarette, and ranks as the most effective single agent.

Withdrawal syndrome.

The time-limited cluster of symptoms—craving, irritability, anxiety, poor concentration, increased appetite—that follows abrupt abstinence in a dependent smoker.

Key Researchers

Albert Bandura

(Stanford University, David Starr Jordan Professor Emeritus of Social Science in Psychology; 1925–2021). Originated the construct of self-efficacy, which became central to understanding who attempts to quit smoking and who sustains abstinence. Wikipedia

Neal L. Benowitz

(University of California, San Francisco, Professor Emeritus of Medicine). A foundational figure in the clinical pharmacology of nicotine, whose work established the mechanisms of nicotine addiction and the basis of replacement therapy. Wikipedia

Carlo C. DiClemente

(University of Maryland, Baltimore County, Professor Emeritus of Psychology). Co-developed the transtheoretical model and its account of self-efficacy and processes of change in smoking cessation and other addictive behaviors. Faculty profile

James O. Prochaska

(University of Rhode Island, Professor Emeritus of Psychology; 1942–2023). Co-developed the transtheoretical model of behavior change from the study of self-quitting smokers, giving the field its enduring stages-of-change framework. Wikipedia

Stephen T. Tiffany

(University at Buffalo, SUNY, SUNY Distinguished Professor Emeritus of Psychology). Formulated the cognitive model of drug urges, reframing craving as the conscious signature of a blocked, automatized drug-use routine. Faculty profile

Robert West

(University College London, Emeritus Professor of Health Psychology). A leading authority on smoking cessation and tobacco addiction, editor-in-chief of Addiction, and a prominent critic of the stages-of-change model's application to quitting. Faculty profile

Frequently Asked Questions

What is smoking cessation?

It is the process of stopping tobacco use and maintaining abstinence over time. In the MeSH classification it is a direct subtype of health behavior, the protective counterpart to the risk behavior of smoking, and it is usually measured by sustained abstinence at six or twelve months rather than by a single quit date (Prochaska & DiClemente, 1983).

Why is quitting smoking so hard?

Because it is defended by nicotine dependence. Repeated nicotine dosing produces neuroadaptation and tolerance, and stopping provokes a reliable withdrawal syndrome—craving, irritability, poor concentration—that peaks in the first week and drives early relapse (Benowitz, 2010; Hughes, 2007).

What are the stages of change?

The transtheoretical model describes an ordered progression from precontemplation (no intention to quit) through contemplation, preparation, action, and maintenance. Relapse returns a person to an earlier stage, so most smokers cycle through the sequence several times before abstinence holds (Prochaska et al., 1992).

Why do people relapse even when they want to quit?

Much of smoking is automatized rather than deliberate. On Tiffany's model, conscious urges surface mainly when the automatic smoking routine is blocked, so a cue in a smoking-associated situation can trigger craving and relapse without any decision to smoke; smoking cues also come to capture attention automatically (Tiffany, 1990; Field & Cox, 2008).

Does nicotine replacement therapy work?

Yes. A large synthesis of randomized trials shows that all forms of NRT raise long-term abstinence over placebo by roughly 50 to 60 percent in relative terms, an effect that is modest per person but reliable and largest when combined with behavioral support (Hartmann-Boyce et al., 2018).

Can e-cigarettes help people quit?

Recent evidence supports them. A landmark trial found e-cigarettes more effective than conventional NRT when both were paired with behavioral support, and a cumulative Cochrane review concludes with high certainty that nicotine-containing e-cigarettes increase quit rates, though their long-term safety and population effects remain debated (Hajek et al., 2019; Lindson et al., 2024).

How is nicotine dependence measured?

The Fagerström Test for Nicotine Dependence estimates physical dependence from a few items, chiefly how soon after waking a person smokes and how many cigarettes they use per day; the score predicts how difficult cessation will be and how much pharmacological support it will require (Heatherton et al., 1991).

Is self-efficacy important for quitting?

Yes. Bandura's work shows that confidence in one's capacity to abstain, especially in tempting situations, predicts both whether a quit attempt is made and whether it is maintained, over and above the intention to quit (Bandura, 1977).

References